Table 3. Hazard ratio for the stroke recurrence in prespecified subgroups.
| Subgroup | No. of patients | No. of events (%) | Hazard ratio (95% CI) | P value for interaction | |
|---|---|---|---|---|---|
| Asprin | Clopidogrel-Asprin | ||||
| Overall | 787 | 43 (10.8%) | 31 (8.1%) | 0.78 (0.48–1.27) | – |
| Fazekas | 0.66 | ||||
| 0–2 | 355 | 19 (10.3%) | 11 (6.5%) | 0.94 (0.41–2.15) | |
| 3–4 | 263 | 18 (13.9%) | 13 (9.8%) | 1.15 (0.50–2.65) | |
| 5–6 | 169 | 6 (7.1%) | 7 (8.3%) | 3.21 (0.53–19.27) | |
| SDWMHs | 0.84 | ||||
| 0–1 | 463 | 27 (11.3%) | 19 (8.5%) | 0.80 (0.41–1.54) | |
| 2–3 | 324 | 16 (9.9%) | 12 (7.4%) | 0.74 (0.29–1.87) | |
| PVWMHs | 0.76 | ||||
| 0–1 | 364 | 18 (9.5%) | 12 (6.9%) | 0.92 (0.40–2.11) | |
| 2–3 | 423 | 25 (11.9%) | 19 (8.9%) | 0.92 (0.47–1.77) | |
The reduction in the risk of stroke with clopidogrel and aspirin, as compared with aspirin alone, was consistent across all major subgroups.